The most common cancers with the TP53 mutations characteristic for the glycidamide-induced mutations were ovarian (10%) and breast (10%) cancer followed by ~ 8% each colorectal and lung cancer (Fig. 2b). Here, TP53 is linked to lung carcinoma.